⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 2024

Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger Meredith McKean Rizwan Haq J. Thaddeus Beck Matthew H. Taylor Jonathan Cohen Daniel W. Bowles Shirish M. Gadgeel Catalin Mihalcioiu Kyriakos P. Papadopoulos Eli L. Diamond Keren Sturtz Gang Feng Stefanie K. Drescher Micaela B. Reddy Bhaswati Sengupta Arnab K. Maity Suzy A. Brown Anurag Singh Eric N. Brown Brian R. Baer Jim Wong Tung‐Chung Mou Wen‐I Wu D Kahn Sunyana Gadal Neal Rosen John J. Gaudino Patrice A. Lee Dylan P. Hartley S. Michael Rothenberg

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S5. Efficacy for BRAF non-V600/Class II and Class III-mutant cancer patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yaeger et al. (2024) studied this question.

synapsesocial.com/papers/68e5968ab6db6435875312d5 https://doi.org/10.1158/2159-8290.26935056.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
2Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
3Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
4Figure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
5Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024